The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead cancer program, and publishes terms for the rights issue
Hørsholm, Denmark, 7 April 2026 – The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by the extraordinary general meeting held on 1 April 2026, resolved on a new issue of units with preferential rights for existing shareholders of approximately SEK 53 million before transaction costs (the “Rights Issue”), in accordance with the intention published by the Company on 27 February 2026, primarily to advance its lead cancer program. Shareholders in ExpreS2ion on the record date, 14 April 2026, will receive forty-seven (47) unit rights for each share held. Five (5) unit rights entitle to subscription of one (1) unit in the Rights Issue. One (1) unit consists of one (1) new share and one (1) warrant of series TO 13. The subscription price in the Rights Issue has been determined to SEK 1.60 per unit, corresponding to SEK 1.60 per share. The warrants of series TO 13 are issued free of charge. If the Rights Issue is fully subscribed, the Company will receive gross proceeds of approximately SEK 53 million before issue costs, which are expected to amount to approximately SEK 9 million. The Company has received subscription commitments from members of the Company's board of directors and management, including CEO Bent U. Frandsen, totalling approximately SEK 0.7 million, corresponding to approximately 1.3 percent of the Rights Issue, and guarantee commitments from external investors totalling SEK 31.1 million, corresponding to approximately 58.6 percent of the Rights Issue. In total, the Rights Issue is thus covered by subscription commitments and guarantee commitments of up to approximately SEK 32 million, corresponding to approximately 60 percent of the Rights Issue.